Effects of naltrexone on the subjective response to amphetamine in healthy volunteers

Journal of Clinical Psychopharmacology

Volumn 24, Issue 6, 2004, Pages 665-669

  Jayaram Lindström, Nitya ^a,b   Wennberg, Peter ^a   Hurd, Yasmin L ^a   Franck, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; METAMINA; NALTREXONE; OPIATE ANTAGONIST; PLACEBO;

ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INHIBITION; FATIGUE; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; SKIN CONDUCTANCE; VISUAL ANALOG SCALE;

ADULT; AFFECT; AMPHETAMINE; ANALYSIS OF VARIANCE; AROUSAL; DOUBLE-BLIND METHOD; EUPHORIA; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; NALTREXONE;

EID: 8744259745     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000144893.29987.e5     Document Type: Article

References (28)

1. Drogutvecklingen i Sverige, rapport 99. Rapport nr10. Centralförbundet för Alkol och Narkotikaupplysning. Stockholm, CAN 2001 [The development of drug use in Sweden, a report].
2. Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Database Syst Rev. 2001;4:CD003026.
3. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. 1987;94:469-492.
4. Balcells-Olivero M, Vezina P. Effects of naltrexone on amphetamine-induced locomotion rearing: acute and repeated injection. Psychopharmacology. 1997;131:230-238.
5. Trujillo KA, Belluzzi JD, Stein L. Naloxone blockade of amphetamine place preference conditioning. Psychopharmacology (Berl). 1991;104:265-274.
6. Kiyatkin EA, Brown PL. Naloxone depresses cocaine self-administration and delays its initiation on the following day. NeuroReport. 2003;14:251-255.
7. Kuzmin AV, Gerrits MA, vanRee JM, et al. Naloxone inhibits the reinforcing and motivational aspects of cocaine addiction in mice. Life Sci. 1997;60:257-264.
8. Schmitz JM, Stotts AL, Rhoades HM, et al. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001;26:167-180.
9. Kosten T, Silverman DG, Fleming J, et al. Intravenous cocaine challenges during naltrexone maintenance: a preliminary study. Biol Psychiatry. 1992;32:543-548.
10. Martin WR, Sloan JW, Sapira JD, et al. Physiologic, subjective, and behavioural effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971;12:245-258.
11. Mayfield DG. The effect of intravenous methamphetamine on mood. Int J Addict. 1973;8:565-568.
12. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49:881-887.
13. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
14. Johanson CE, Uhlenhuth EH. Drug preference and mood in humans: D-amphetamine. Psychopharmacology (Berl). 1980;71:275-279.
15. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego: Educational and Industrial Testing Service; 1971.
16. Rush CR, Essman WD, Simpson CA, et al. Reinforcing and subject-rated effects of methylphenidate and D-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol. 2001;21:273-286.
17. Cardenas L, Houle S, Kapur S, et al. Oral D-amphetamine causes prolonged displacement of [11C] raclopride as measured by PET. Synapse. 2004;51:27-31.
18. Physicians Desk Reference. Movtvale, NJ: Medical Economics Data; 2002.
19. Meyer MC, Straughn AB, Lo MW, et al. Bioequivalence, dose-proportionality and pharmacokinetics of naltrexone after oral administration. Clin Psychiatry. 1984;45:15-19.
20. McCaul ME, Wand GS, Eissenberg T, et al. Naltrexone alters subjective and psychomotor response to alcohol in heavy drinking subjects. Neuropsychopharmacology. 2000;22:480-491.
21. Hurd YL, Ungerstedt U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol. 1989;166:251-260.
22. Hitzemann R, Curell J, Hom D, et al. Effects of naloxone on D-amphetamine- and apomorphine-induced behavior. Neuropharmacology. 1982;21:1005-1011.
23. Sofuoglu M, Singha A, Kosten TR, et al. Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacol Biochem Behav. 2003;75:801-808.
24. Balcells-Olivero M, Vezina P. Effects of naltrexone on amphetamine-induced locomotion and rearing: acute and repeated injections. Psychopharmacology (Berl). 1997;131:230-238.
25. Davidson D, Swift R, Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res. 1996;20:732-739.
26. Hollister LE, Johnson K, Boukhabza D, et al. Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend. 1981;8:37-41.
27. Doty P, Kirk JM, Cramblett MJ, et al. Behavioral responses to ethanol in light and moderate social drinkers following naltrexone pre-treatment. Drug Alcohol Depend. 1997;47:109-116.
28. DeWit H, Svenson J, York A. Non-specific effect of naltrexone on ethanol consumption in social drinkers. Psychopharmacology (Berl). 1999;146:33-41.